The clinical success of CGRP receptor antagonists and anti-CGRP monoclonal antibodies in migraine treatment demonstrates the therapeutic potential of targeting neuropeptide signaling pathways (32), suggesting similar approaches may be applicable to herpes zoster-related pain conditions and other neurogenic inflammatory disorders. This evidence concerns the gene NPS and migraine disorder.